Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
| ▸ | CIT | O14578 | 2/20 | 0.36 |
| ▸ | GAK | O14976 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14802467 | 0.81 | WNT3A (0.53) | LOXL2AAK1WNT3A | |
| SCHEMBL23396657 | 0.78 | LOXL2 (0.41) | LOXL2AAK1WNT3A | |
| SCHEMBL1912374 | 0.78 | LOXL2 (0.56) | LOXL2AAK1WNT3A | |
| SCHEMBL17372392 | 0.73 | LOXL2 (0.57) | LOXL2AAK1CITGAKMKNK1 | |
| SCHEMBL30398944 | 0.73 | LOXL2 (0.57) | LOXL2AAK1CITGAKMKNK1 | |
| SCHEMBL1912424 | 0.72 | LOXL2 (0.53) | LOXL2AAK1WNT3A | |
| Hydrochloric Acid SCHEMBL15757016 | 0.72 | LOXL2 (0.55) | LOXL2AAK1CITGAKMKNK1 | |
| SCHEMBL1912413 | 0.68 | WNT3A (0.52) | WNT3A | |
| SCHEMBL17981898 | 0.67 | LOXL2 (0.45) | LOXL2SLC6A2CHRNA7 | |
| Hydrochloric Acid SCHEMBL249352 | 0.67 | WNT3A (0.51) | WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | LOXL2 1850/4885AAK1 609/4885WNT3A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.